More than 130 suppliers
ISO certified
In-house tech support
we Connect you
Bio-Connect
ProductsBack/Semaglutide . AcOH [910463-68-2]
Chemical Structure
Chemical Structure
Chemical Structure

Semaglutide . AcOH [910463-68-2]

Research Use Only
AG-CP3-0032
AdipoGen Life Sciences
Estimated Purity>95% (HPLC)
DownloadDatasheet
DownloadMSDS
Product group Chemicals
Molecular Weight4113.6 . 60.0
Price on request
Packing Size
Large volume orders?
Order with a bulk request
More than 130 suppliers
ISO certified
In-house tech support

Overview

  • Supplier
    AdipoGen Life Sciences
  • Product Name
    Semaglutide . AcOH [910463-68-2]
  • Delivery Days Customer
    10
  • Certification
    Research Use Only
  • Estimated Purity
    >95% (HPLC)
  • Hazard Information
    Non-hazardous
  • Molecular Formula
    C187H291N45O59 . C2H4O2
  • Molecular Weight
    4113.6 . 60.0
  • Scientific Description
    Chemical. CAS: 910463-68-2 (parent). Formula: C187H291N45O59 . C2H4O2. MW: 4113.6 . 60.0. Synthetic. Glucagon-like peptide-1 (GLP-1) receptor agonist. Antidiabetic agent against type 2 diabetes (T2D). Stimulates insulin and suppresses glucagon secretion in a glucose-dependent manner. Longer-acting alternative to liraglutide. Chemically similar to glucagon-like peptide-1 (GLP-1), with two amino acid substitutions compared to human GLP-1 (Aib(8), Arg(34)) and derivatized at lysine 26. Antiobesity activity. Reduces energy intake, likely mechanisms for semaglutide-induced weight loss include less appetite and food cravings, better control of eating and lower relative preference for fatty, energy-dense foods. - Glucagon-like peptide-1 (GLP-1) receptor agonist. Antidiabetic agent against type 2 diabetes (T2D). Stimulates insulin and suppresses glucagon secretion in a glucose-dependent manner. Longer-acting alternative to liraglutide. Chemically similar to glucagon-like peptide-1 (GLP-1), with two amino acid substitutions compared to human GLP-1 (Aib(8), Arg(34)) and derivatized at lysine 26. Antiobesity activity. Reduces energy intake, likely mechanisms for semaglutide-induced weight loss include less appetite and food cravings, better control of eating and lower relative preference for fatty, energy-dense foods.
  • SMILES
    CC[C@@H]([C@@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(NCC(N[C@H](C(NCC(O)=O)=O)CCCNC(N)=N)=O)=O)CCCNC(N)=N)=O)C(C)C)=O)CC(C)C)=O)CC1=CNC2=C1C=CC=C2)=O)C)=O)NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC(CNC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@H](C(C)C)NC([C@@H](NC([C@@H](NC([C@H]([C@H](O)C)NC([C@@H](NC([C@H]([C@H](O)C)NC(CNC([C@@H](NC(C(C)(NC([C@H](CC3=CNC=N3)N)=O)C)=O)CCC(O)=O)=O)=O)=O)CC4=CC=CC=C4)=O)=O)CO)=O)CC(O)=O)=O)=O)CO)=O)CO)=O)CC5=CC=C(C=C5)O)=O)CC(C)C)=O)CCC(O)=O)=O)=O)CCC(N)=O)=O)C)=O)C)=O)CCCCNC(COCCOCCNC(COCCOCCNC(CC[C@H](C(O)=O)NC(CCCCCCCCCCCCCCCCC(O)=O)=O)=O)=O)=O)=O)CCC(O)=O)=O)CC6=CC=CC=C6)=O)C.O=C(C)O
  • Storage Instruction
    2°C to 8°C,-20°C
  • UNSPSC
    12352200

References

  • Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide: J. Lau, et al.; J. Med. Chem. 58, 7370 (2015)
  • Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes: S.P. Marso, et al.; N. Engl. J. Med. 375, 1834 (2016)
  • Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity: J. Blundell, et al.; Diabetes Obes. Metab. 19, 1242 (2017)
  • Semaglutide-the “new kid on the block” in the field of glucagon-like peptide-1 receptor agonists? C. Guja & R. Danciulescu Miulescu; Ann. Transl. Med. 5, 475 (2017) (Review)